USFDA approves first anti-epilepsy pill manufactured with 3D printer
Aprecia’s Spritam becomes first anti-epilepsy pill manufactured with 3D printer to get the US Food and Drug Administration (USFDA) approval.
The specified porous structure of the pill ‘Spritam’ was developed by using ZipDose 3D printing technology by Aprecia Pharmaceuticals.
Designing detail structure of the Spritam pill made it possible for Aprecia to develop a pill that dissolve faster and delivers up to 1000 mg of medication in a single dose.
The pill is supposed to reach in the market by 2016.
- Pill developed under 3D printer will reduce the costing of designing and creating complex structure in lesser time.
- This pill will improve the medications by delivering exact amount of content to the children and the elders.
- It will open endless possibilities of personalised medications.
ZipDose 3D printing technology:
The Massachusetts Institute of Technology (MIT) was first to develop Powder-liquid three-dimensional printing (3DP) technology in 1980s. Aprecia started developing ZipDose 3DP technology in 2007 which was designed to enable delivery of high-dose medications in a rapidly disintegrating form. This technology enables the aqueous fluid to stitch together multiple layers of powder to create a wide range of products.